Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.
Expanding their 2017 option and equity deal, Novartis AG is to take Ionis Pharmaceuticals Inc. spinout Akcea Therapeutics Inc.’s novel antisense cardiovascular product TQJ230 into a Phase III cardiovascular outcomes study after exercising an option to the candidate on Feb. 25
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?